Brace Pharmaceuticals is pleased to announce it’s investment in Tyrogenex Inc

WEST PALM BEACH, Fla., Jun 19, 2014 (BUSINESS WIRE) — Tyrogenex Inc. , an Xcovery Group company focused on discovering and developing novel patented cancer and ophthalmic therapeutics, today announced it received $15 million in Series D financing from Brace Pharma, the U.S. investment company of EMS S/A, the largest pharmaceutical company in Brazil. Vinzenz Ploerer, president and CEO of Brace Pharma, was appointed to the Board of Directors for Tyrogenex, Inc.

Read more